HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY
The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | VESCI, Loredana MILAZZO, Ferdinando Maria FALTONI, Valentina GIANNINI, Giuseppe PETRICCI, Elena DE SANTIS, Rita TADDEI, Maurizio |
| description | The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.
La présente invention concerne de nouveaux conjugués anticorps-médicaments à base d'inhibiteurs d'histone désacétylase (iHDAC), en particulier avec des anticorps dirigés contre les récepteurs ErbB1, ErbB2 et ErbB3, des compositions pharmaceutiques comprenant lesdits anticorps ainsi que leur utilisation dans le traitement du cancer ou d'une tumeur et d'autres maladies où une modulation d'une ou de plusieurs isoformes d'histone désacétylase peut être efficace pour des interventions thérapeutiques. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2018178060A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2018178060A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2018178060A13</originalsourceid><addsrcrecordid>eNrjZPDwcHF0VvD08_B08gzxDwrWdXIMdnVRcPQL8XTyd4lUcAkKdVdw9vfzCnV3DHENVtBwdHEu1gTKuyiEBrsCNSqEeLgGOQZE8jCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-HB_IwNDC0NzCwMzA0dDY-JUAQCD4S1X</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY</title><source>esp@cenet</source><creator>VESCI, Loredana ; MILAZZO, Ferdinando Maria ; FALTONI, Valentina ; GIANNINI, Giuseppe ; PETRICCI, Elena ; DE SANTIS, Rita ; TADDEI, Maurizio</creator><creatorcontrib>VESCI, Loredana ; MILAZZO, Ferdinando Maria ; FALTONI, Valentina ; GIANNINI, Giuseppe ; PETRICCI, Elena ; DE SANTIS, Rita ; TADDEI, Maurizio</creatorcontrib><description>The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.
La présente invention concerne de nouveaux conjugués anticorps-médicaments à base d'inhibiteurs d'histone désacétylase (iHDAC), en particulier avec des anticorps dirigés contre les récepteurs ErbB1, ErbB2 et ErbB3, des compositions pharmaceutiques comprenant lesdits anticorps ainsi que leur utilisation dans le traitement du cancer ou d'une tumeur et d'autres maladies où une modulation d'une ou de plusieurs isoformes d'histone désacétylase peut être efficace pour des interventions thérapeutiques.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181004&DB=EPODOC&CC=WO&NR=2018178060A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181004&DB=EPODOC&CC=WO&NR=2018178060A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>VESCI, Loredana</creatorcontrib><creatorcontrib>MILAZZO, Ferdinando Maria</creatorcontrib><creatorcontrib>FALTONI, Valentina</creatorcontrib><creatorcontrib>GIANNINI, Giuseppe</creatorcontrib><creatorcontrib>PETRICCI, Elena</creatorcontrib><creatorcontrib>DE SANTIS, Rita</creatorcontrib><creatorcontrib>TADDEI, Maurizio</creatorcontrib><title>HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY</title><description>The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.
La présente invention concerne de nouveaux conjugués anticorps-médicaments à base d'inhibiteurs d'histone désacétylase (iHDAC), en particulier avec des anticorps dirigés contre les récepteurs ErbB1, ErbB2 et ErbB3, des compositions pharmaceutiques comprenant lesdits anticorps ainsi que leur utilisation dans le traitement du cancer ou d'une tumeur et d'autres maladies où une modulation d'une ou de plusieurs isoformes d'histone désacétylase peut être efficace pour des interventions thérapeutiques.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPDwcHF0VvD08_B08gzxDwrWdXIMdnVRcPQL8XTyd4lUcAkKdVdw9vfzCnV3DHENVtBwdHEu1gTKuyiEBrsCNSqEeLgGOQZE8jCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-HB_IwNDC0NzCwMzA0dDY-JUAQCD4S1X</recordid><startdate>20181004</startdate><enddate>20181004</enddate><creator>VESCI, Loredana</creator><creator>MILAZZO, Ferdinando Maria</creator><creator>FALTONI, Valentina</creator><creator>GIANNINI, Giuseppe</creator><creator>PETRICCI, Elena</creator><creator>DE SANTIS, Rita</creator><creator>TADDEI, Maurizio</creator><scope>EVB</scope></search><sort><creationdate>20181004</creationdate><title>HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY</title><author>VESCI, Loredana ; MILAZZO, Ferdinando Maria ; FALTONI, Valentina ; GIANNINI, Giuseppe ; PETRICCI, Elena ; DE SANTIS, Rita ; TADDEI, Maurizio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2018178060A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2018</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>VESCI, Loredana</creatorcontrib><creatorcontrib>MILAZZO, Ferdinando Maria</creatorcontrib><creatorcontrib>FALTONI, Valentina</creatorcontrib><creatorcontrib>GIANNINI, Giuseppe</creatorcontrib><creatorcontrib>PETRICCI, Elena</creatorcontrib><creatorcontrib>DE SANTIS, Rita</creatorcontrib><creatorcontrib>TADDEI, Maurizio</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>VESCI, Loredana</au><au>MILAZZO, Ferdinando Maria</au><au>FALTONI, Valentina</au><au>GIANNINI, Giuseppe</au><au>PETRICCI, Elena</au><au>DE SANTIS, Rita</au><au>TADDEI, Maurizio</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY</title><date>2018-10-04</date><risdate>2018</risdate><abstract>The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.
La présente invention concerne de nouveaux conjugués anticorps-médicaments à base d'inhibiteurs d'histone désacétylase (iHDAC), en particulier avec des anticorps dirigés contre les récepteurs ErbB1, ErbB2 et ErbB3, des compositions pharmaceutiques comprenant lesdits anticorps ainsi que leur utilisation dans le traitement du cancer ou d'une tumeur et d'autres maladies où une modulation d'une ou de plusieurs isoformes d'histone désacétylase peut être efficace pour des interventions thérapeutiques.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2018178060A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A30%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=VESCI,%20Loredana&rft.date=2018-10-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2018178060A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |